| Page 19 | Aplastic Anemia and MDS International Foundation

AAMDS Amy Gaynor Research Fund

Amy Gaynor was a tenth grade honor student at Cleveland Heights High School as well as a member of the girls’ varsity tennis team and swim cadets.  She belonged to an Amateur Athletic Union swim team and volunteered to teach swimming to children with disabilities. Amy was also a fine pianist.  But in 1977, at age 15, Amy was diagnosed with

Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia

Author(s): 
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony S
Primary Author: 
Eytan M. Stein
Journal Title: 
Blood
Original Publication Date: 
May 2017

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ~12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, leading to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes.

Bone Marrow Diseases: 

New data presented at ASCO on secondary MDS/AML

Cancer patients with secondary malignancies have limited access to data regarding the possibility of their myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or both, being caused by the usage of certain chemotherapeutic agents that could possibly interfere with DNA.

New data concludes, though, that the incidence of MDS and AML in ovarian and breast cancer patients was higher in patients exposed to DNA damaging agents.

Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia

Author(s): 
Jain P, Klotz J, Dunavin N, Lu K, Koklanaris E, Draper D, Superata J, Chinian F, Yu Q, Keyvanfar K, Wong S, Muranski P, Barrett AJ, Ito S, Battiwalla M
Primary Author: 
Jain P
Journal Title: 
Leuk Res Rep
Original Publication Date: 
Apr 2017

Patients with high risk

Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes.

Author(s): 
DeZern AE, Binder G, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J, Smith BD
Primary Author: 
DeZern AE
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
May 2017

Transfusion dependence (TD) among

Bone Marrow Diseases: 

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Author(s): 
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP
Primary Author: 
Sekeres MA
Journal Title: 
J Clin Oncol
Original Publication Date: 
May 2017

Purpose

Bone Marrow Diseases: 

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation.

Author(s): 
Mohanan E, Panetta JC, Lakshmi KM, Edison ES, Korula A, Fouzia NA, Abraham A, Viswabandya A, Mathews V, George B, Srivastava A, Balasubramanian P
Primary Author: 
Mohanan E
Journal Title: 
Bone Marrow Transplant
Original Publication Date: 
May 2017

Although hematopoietic stem cell transplantation (HSCT) with a conditioning regimen consisting of

Bone Marrow Diseases: